Background: Advances in oncological therapy have significantly improved breast cancer survival; therefore comorbid conditions are becoming more relevant. We investigated the prevalence of prior cardiovascular diseases and risk factors in patients with breast cancer compared to those in the general female population in Germany. Methods: The PASSOS heart study is a retrospective multicenter cohort study on cardiac late effects in breast cancer patients treated between 1998 and 2008. We analyzed the frequencies of cardiac diseases and cardiovascular risk factors in patients from this cohort as documented in anesthesia protocols compared to self-reported frequencies in the general female population in Germany. Results: 3,496 patients aged between 40 and 79 years who underwent breast surgery were considered for analysis. The age-standardized prevalence of cardiac diseases or cardiovascular risk factors was 6.75 versus 7.52% and 69 versus 80.92%, respectively. Coronary heart disease (3.96 vs. 5.18%) and angina pectoris (0.37 vs. 1.03%) prevalence was lower in breast cancer patients, while non-fatal myocardial infarction (2.06 vs. 1.81%) and stroke (2.64 vs. 2.34%) were more frequent (not statistically significant). Conclusion: Pre-existing cardiac diseases and cardiovascular risk factors are common in both study populations, being slightly less frequent in the PASSOS cohort. When making therapy decisions, the cardiac risk profile should be carefully monitored and taken into account.

1.
RKI: Krebs in Deutschland 2011/2012. Robert Koch-Institut und die Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V., 2015.
2.
Van Ewijk RJ, Schwentner L, Wockel A, Konig J, Kreienberg R, Blettner M: Trends in patient characteristics, treatment and survival in breast cancer in a non-selected retrospective clinical cohort study of 2,600 patients. Arch Gynecol Obstet 2013;287:103-110.
3.
Patnaik JL, Byers T, Diguiseppi C, Denberg TD, Dabelea D: The influence of comorbidities on overall survival among older women diagnosed with breast cancer. J Natl Cancer Inst 2011;103:1101-1111.
4.
Darby SC, Ewertz M, McGale P, Bennet AM, Blom-Goldman U, Bronnum D, Correa C, Cutter D, Gagliardi G, Gigante B, Jensen MB, Nisbet A, Peto R, Rahimi K, Taylor C, Hall P: Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med 2013;368:987-998.
5.
Schlitt A, Jordan K, Vordermark D, Schwamborn J, Langer T, Thomssen C: Kardiotoxizität onkologischer Therapien. Dtsch Arztebl Int 2014;111:161-168.
6.
Schmitz KH, Prosnitz RG, Schwartz AL, Carver JR: Prospective surveillance and management of cardiac toxicity and health in breast cancer survivors. Cancer 2012;118:2270-2276.
7.
Obi N, Gornyk D, Heinz J, Vrieling A, Seibold P, Chang-Claude J, Flesch-Janys D: Determinants of newly diagnosed comorbidities among breast cancer survivors. J Cancer Surviv 2014;8:384-393.
8.
Merzenich H, Bartkowiak D, Schmidberger H, Schmidt M, Schwentner L, Wiegel T, Woeckel A, Wollschlager D, Blettner M: 3D conformal radiotherapy is not associated with the long-term cardiac mortality in breast cancer patients: a retrospective cohort study in Germany (PASSOS-Heart Study). Breast Cancer Res Treat 2017;161:143-152.
9.
Wollschlager D, Merzenich H, Schwentner L, Janni W, Wiegel T, Bartkowiak D, Wockel A, Schmidt M, Schmidberger H, Blettner M: Self-reported long-term cardiac morbidity in breast cancer patients: a retrospective cohort study in Germany (PASSOS Heart Study). Breast Cancer Res Treat 2017;163:595-604.
10.
Kurzeder C, König J, Wischnewsky M, Koretz K, Moeller P, Wiegel T, Brambs HJ, Blettner M, Kreienberg R: Impact of guideline conform local-regional treatment on survival of breast cancer patients: an analyses of the BRENDA-study group. J Clin Oncol 2008;26:abstr 612.
11.
Schwentner L, Wockel A, Konig J, Janni W, Ebner F, Blettner M, Kreienberg R, van Ewijk R: Adherence to treatment guidelines and survival in triple-negative breast cancer: a retrospective multi-center cohort study with 9,156 patients. BMC Cancer 2013;13:487.
12.
Kamtsiuris P, Lange M, Hoffmann R, Schaffrath Rosario A, Dahm S, Kuhnert R, Kurth BM: The first wave of the German Health Interview and Examination Survey for Adults (DEGS1): sample design, response, weighting and representativeness (Article in German). Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2013;56:620-630.
13.
Gosswald A, Schienkiewitz A, Nowossadeck E, Busch MA: Prevalence of myocardial infarction and coronary heart disease in adults aged 40-79 years in Germany: results of the German Health Interview and Examination Survey for Adults (DEGS1) (Article in German). Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2013;56:650-655.
14.
Lundqvist A, Andersson E, Ahlberg I, Nilbert M, Gerdtham U: Socioeconomic inequalities in breast cancer incidence and mortality in Europe - a systematic review and meta-analysis. Eur J Public Health 2016;26:804-813.
15.
Huang BZ, Camp MS: Burden of preoperative cardiovascular disease risk factors on breast cancer surgery outcomes. J Surg Oncol 2016;114:144-149.
16.
Janssen-Heijnen MLG, Maas HAAM, Houterman S, Lemmens VEPP, Rutten HJT, Coebergh JWW: Comorbidity in older surgical cancer patients: influence on patient care and outcome. Eur J Cancer 2007;43:2179-2193.
17.
Stang A, Stang M: Kardiovaskuläre Risikofaktoren im Bundeslandvergleich. Dtsch Arztebl Int 2014;111:530-536.
18.
Suzuki R, Orsini N, Saji S, Key TJ, Wolk A: Body weight and incidence of breast cancer defined by estrogen and progesterone receptor status - a meta-analysis. Int J Cancer 2009;124:698-712.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.